Market Place
Sourcing Support
HUTCHMED Announces NDA Acceptance In China With Priority Review
29 Apr 2026 //
GLOBENEWSWIRE
HUTCHMED Reports 2025 Full Year Results And Business Updates
05 Mar 2026 //
GLOBENEWSWIRE
HUTCHMED Starts Global Trial Of HMPL-A580 In Solid Tumor Patients
04 Mar 2026 //
PHARMIWEB
HUTCHMED To Announce 2025 Final Results
06 Feb 2026 //
PHARMIWEB
Hutchmed`s NDA Acceptance in China with Status for Savolitinib
30 Dec 2025 //
GLOBENEWSWIRE
Hutchison China Meditech Showcases Clinical Data At 2025 ESMO
26 Nov 2025 //
GLOBENEWSWIRE
Hutchison China Meditech Announces Board Committee Appointment
14 Oct 2025 //
GLOBENEWSWIRE
HUTCHMED R&D Updates Presentation on October 31, 2025
11 Sep 2025 //
GLOBENEWSWIRE
Hutchmed Announces Appointment of Acting Chief Executive Officer
24 Aug 2025 //
GLOBENEWSWIRE
HUTCHMED Reports 2025 Interim Results
07 Aug 2025 //
GLOBENEWSWIRE
Hutchmed to Announce 2025 Half-Year Financial Results
03 Jul 2025 //
GLOBENEWSWIRE
Hutchmed Gets China Nod for Orpathys + Tagrisso Combo
30 Jun 2025 //
GLOBENEWSWIRE
Hutchmed Highlights SACHI Phase III Data at 2025 ASCO Meeting
01 Jun 2025 //
GLOBENEWSWIRE
Hutchmed Highlights Clinical Data at 2025 ASCO Annual Meeting
22 May 2025 //
GLOBENEWSWIRE
Hutchmed Data at AACR Annual Meeting 2025
23 Apr 2025 //
GLOBENEWSWIRE
Hutchmed: NMPA Approves TAZVERIK® for Follicular Lymphoma
21 Mar 2025 //
GLOBENEWSWIRE
Retirement of Independent Directors and Board Committee Changes
20 Mar 2025 //
GLOBENEWSWIRE
HUTCHMED Reports 2024 Full Year Results and Business Updates
19 Mar 2025 //
GLOBENEWSWIRE
Hutchmed Completes Enrollment In Ph2 Fanregratinib Study In China
06 Mar 2025 //
GLOBENEWSWIRE
Hutchmed Appoints Independent Non-Executive Board Member
05 Mar 2025 //
GLOBENEWSWIRE
HUTCHMED to Announce 2024 Final Results
19 Feb 2025 //
GLOBENEWSWIRE
Hutchmed Announces US$608 M Divestment of Non-Core Joint Venture
02 Jan 2025 //
GLOBENEWSWIRE
Hutchmed`s Priority Review For Orpathys-Tagrisso In Lung Cancer
01 Jan 2025 //
GLOBENEWSWIRE
Hutchmed to Receive Milestone Payment for FRUZAQLA® Reimbursement
12 Dec 2024 //
GLOBENEWSWIRE
Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso
11 Dec 2024 //
GLOBENEWSWIRE
Hutchmed`s ORPATHYS® Maintains Inclusion In China’s NDL
28 Nov 2024 //
GLOBENEWSWIRE
Hutchmed Announces Launch by Takeda of FRUZAQLA in Japan
21 Nov 2024 //
GLOBENEWSWIRE
Hutchmed Appoints Independent Non-Executive Director To Board
20 Nov 2024 //
GLOBENEWSWIRE
Hutchmed Highlights Clinical Data at 2024 ASH & ESMO Asia
05 Nov 2024 //
GLOBENEWSWIRE
HUTCHMED to Receive Milestone Payment for FRUZAQLA® Sales
31 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
16 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Japan Approval For FRUZAQLA By Takeda
23 Sep 2024 //
GLOBENEWSWIRE
Eli Lilly Partner Hutchmed Scraps China Stomach Cancer Filing
31 Aug 2024 //
FIERCE PHARMA
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
29 Aug 2024 //
GLOBENEWSWIRE
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
21 Aug 2024 //
GLOBENEWSWIRE
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
31 Jul 2024 //
GLOBENEWSWIRE
Hutchmed`s NDA For Tazemetostat In Follicular Lymphoma Accepted In China
03 Jul 2024 //
GLOBENEWSWIRE
HUTCHMED to Announce 2024 Half-Year Financial Results
26 Jun 2024 //
GLOBENEWSWIRE
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
24 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Phase III ESLIM-01 Results Published In Lancet Haematology
16 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates Phase 1 Trial Of Menin Inhibitor In China
06 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED`s FRUTIGA Phase III Results Published In Nature Medicine
02 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
23 May 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Chairman Retirement, Appointments & Committee Changes
17 May 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024
16 May 2024 //
GLOBENEWSWIRE
HUTCHMED, Hengrui Phase 2/3 Pancreatic Cancer Trial Begins
13 May 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates RAPHAEL Phase 3 AML Trial In China
13 May 2024 //
GLOBENEWSWIRE
HUTCHMED Appoints Director, Board Committee Member
08 May 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
05 Apr 2024 //
GLOBENEWSWIRE
HUTCHMED & Innovent NDA Acceptance in China for Fruquintinib with Sintilimab
01 Apr 2024 //
GLOBENEWSWIRE
China NMPA accepts for review Hutchmed’s sNDA for savolitinib
29 Mar 2024 //
PHARMABIZ
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
27 Mar 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates ESLIM-02 Phase II/III Trial of Sovleplenib in China
21 Mar 2024 //
GLOBENEWSWIRE
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
28 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib
06 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates
02 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED to Announce 2023 Final Results
01 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong
29 Jan 2024 //
GLOBENEWSWIRE
Hutchmed Announces NDA Acceptance in China for Sovleplenib
10 Jan 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia
30 Nov 2023 //
GLOBENEWSWIRE
